Viking Therapeutics News

8,00 +0,25% +0,02 €
22.03.19 15:02:35 Uhr Frankfurt | Orderbuch | Mehr Kurse »
WKN: A12GD6
ISIN: US92686J1060
US-Symbol: VKTX
Typ: Aktie

Viking Therapeutics News

  
13.03.19 Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update PR Newswire
06.03.19 Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019 PR Newswire
26.02.19 Viking Therapeutics to Participate in Upcoming Investor Conferences and Events PR Newswire
12.02.19 Gilead: Der nächste Schock - diese Aktien profitieren Der Aktionär
01.02.19 3 starke Aktien für unter 10 Dollar The Motley Fool
07.01.19 Viking: Cash für NASH - Aktienanalyse Aktiencheck
02.01.19 Viking Therapeutics to Present at Biotech Showcase 2019 PR Newswire
02.01.19 Viking Therapeutics: Chronische Schwäche zum Aufbau einer spekulativen Position nutzen - Aktienanalyse Aktiencheck
12.11.18 Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-​Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-​Cholesterol in Oral Late-​Breaker Presentation at The Liver Meeting® 2018 PR Newswire
07.11.18 Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
31.10.18 Viking Therapeutics to Report Financial Results for Third Quarter 2018 on November 7, 2018 PR Newswire
29.10.18 Novartis und Pfizer: Der Kampf um den 40-Milliarden-​Dollar-Markt Der Aktionär
26.10.18 3 starke Small-​Cap-Aktien, die man im Oktober kaufen kann The Motley Fool
08.10.18 Viking Therapeutics Announces Data from In Vivo Study of VK2809 Presented at Oral Plenary Session of the 88th Annual Meeting of American Thyroid Association (ATA) PR Newswire
04.10.18 Viking Therapeutics Announces VK2809 Phase 2 Study Results Selected for Oral Late-​Breaker Presentation at The Liver Meeting® 2018 PR Newswire
02.10.18 Michel Doepke: Gilead, Sangamo, Viking, Sarepta, Loxo Oncology - das müssen Sie aktuell wissen Der Aktionär TV
01.10.18 Viking Therapeutics Presents Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture in Plenary Oral Presentation at ASBMR 2018 Annual Meeting PR Newswire
26.09.18 Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
24.09.18 Viking Therapeutics: Günstiger als die Konkurrenz - Aktienanalyse Aktiencheck
24.09.18 Cash mit NASH: So geht es beim Fettleber-​Hot-Stock Viking Therapeutics weiter Der Aktionär
20.09.18 Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock PR Newswire
19.09.18 Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
18.09.18 Viking Therapeutics: Kursexplosion - Was ist los? Aktienanalyse Aktiencheck
18.09.18 BREAKING: AKTIONÄR-​Hot-Stock Viking Therapeutics explodiert um 130 Prozent - die Hintergründe! Der Aktionär
18.09.18 US-Markt: Dow Jones, Viking Therapeutics, Madrigal, Wal-Mart, Amazon, Alphabet, Netflix Der Aktionär TV
18.09.18 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-​Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-​Cholesterol PR Newswire
28.08.18 Viking Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
09.08.18 Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
02.08.18 Viking Therapeutics to Report Financial Results for Second Quarter 2018 on August 9, 2018 PR Newswire
25.07.18 Sollten die Biotech-​Investoren eine Verwässerung fürchten? The Motley Fool
21.07.18 3 Top-​Biotech-Aktien zum Kauf für das 2. Halbjahr 2018 The Motley Fool
17.07.18 Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting PR Newswire
25.06.18 Jetzt ist die Zeit, diese drei Aktien zu kaufen The Motley Fool
19.06.18 3 Wachstumsaktien zum Dumpingpreis The Motley Fool
12.06.18 Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
07.06.18 Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock PR Newswire
06.06.18 Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
05.06.18 Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-​Alcoholic Fatty Liver Disease PR Newswire
09.05.18 Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
02.05.18 Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018 PR Newswire
07.03.18 Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update PR Newswire
06.03.18 Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
28.02.18 Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2017 on March 7, 2018 PR Newswire
07.02.18 Viking Therapeutics to Present at 2018 BIO CEO & Investor Conference PR Newswire
06.02.18 Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
02.02.18 Viking Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock PR Newswire
01.02.18 Viking Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
02.01.18 Viking Therapeutics to Present at Biotech Showcase 2018 PR Newswire
11.12.17 Viking Therapeutics Announces Closing of Public Offering of Common Stock PR Newswire
06.12.17 Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock PR Newswire

Newssuche

  

Videos

  
22.03.19 -2,27%
XM Inside Markets: "Viele Kranke im Dax, Dow sensationell, Deutsche Bank ab 8,50 Euro ein Kauf"